Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2007 2008 2009 2010 2011 2012 TTM 2013E 2014E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +29.1%

FINANCIAL BRIEF: For the six months ended 30 June 2013, Cyprotex plc revenues increased 22% to L4.5M. Net income totaled L298K vs. loss of L222K. Revenues reflect Rest of Europe segment increase of 55% to L1.6M, United Kingdom segment increase of 7% to L916K. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score  
B+
B+

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '13) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2013
31st Dec 2014

Price Target: N/A Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +30.0% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for Cyprotex
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Edison Investment Research , N+1 Singer Jens Lindqvist Sheena Berry ,

Cyprotex PLC is a holding company. The Company’s trading subsidiaries are Cyprotex Discovery Limited and Apredica LLC. The principal activities of the Company are that of providing in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) information to the pharmaceutical and biotechnology industries. Cyprotex provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. Cyprotex serves all types and sizes of drug-discovery organizations, as well as academic and not-for-profit laboratories. In January 2014, the Company acquired business and assets of CeeTox, Inc, a division of North American Science Associates, Inc.

Directors: Anthony Baxter (CEO) 53, John Dootson (CFO) 51, Mark Warburton (Secy.) 60,

No. of Employees: 73 No. of Shareholders: n/a


Last Annual December 31st, 2012
Last Interim June 30th, 2013
Shares in Issue 224,340,569
Free Float 86.5m (38.5%)
ISIN GB0031214470
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

CRX Share Price Performance CRX Quote
5.63p
0.0  0.0%
Traded 8:03am · Minimum 15 min delayed · NMS: 30.0k

Latest CRX News Announcements (delayed)

Upcoming CRX Events
Thursday 24th July, 2014
Cyprotex PLC Annual General Meeting
Monday 4th August, 2014 (estimate)
Interim 2014 Cyprotex PLC Earnings Release

Recent ↓
Tuesday 25th March, 2014
Preliminary 2013 Cyprotex PLC Earnings Release
Thursday 23rd January, 2014
Cyprotex PLC Trading Update
Thursday 26th September, 2013
Cyprotex PLC General Meeting
Wednesday 21st August, 2013
Cyprotex PLC Convertible Offering Filing
Wednesday 7th August, 2013
Interim 2013 Cyprotex PLC Earnings Release
Tuesday 16th July, 2013
Cyprotex PLC Annual General Meeting
Thursday 20th June, 2013
Cyprotex PLC H1 2013 Trading Update
Thursday 21st March, 2013
Preliminary 2012 Cyprotex PLC Earnings Release
Thursday 13th December, 2012
Cyprotex PLC Trading Update
Thursday 6th September, 2012
Interim 2012 Cyprotex PLC Earnings Presentation (London)


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy CRX

Access CRX Analytics Now!

FREE TRIAL or TAKE THE TOUR